J Clin Endocrinol Metab 97:3097–3106PubMedCrossRef 6. Ito M, Nakata T, Nishida A, Uetani M (2011) Age-related changes in bone density, geometry and biomechanical properties of the proximal femur: CT-based 3D hip structure analysis in normal postmenopausal women. Bone 48:627–630PubMedCrossRef 7. Ito M, Wakao N, Hida T, Matsui Y, Abe Y, Aoyagi K, Uetani M, Harada A (2010) Analysis of hip geometry by clinical CT for the assessment of hip fracture risk in elderly Japanese women. www.selleckchem.com/screening/kinase-inhibitor-library.html Bone 46:453–457PubMedCrossRef
8. Borggrefe J, Graeff C, Nickelsen TN, Marin F, Gluer CC (2010) Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. JBMR 25:472–481CrossRef 9. Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, Beck TJ (2005) Effects of teriparatide [rhPTH(1–34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 36:948–958PubMedCrossRef 10. Ito M, Nakamura T, Fukunaga M, Shiraki M, Matsumoto T (2011) Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT. Bone 49:328–334PubMedCrossRef 11. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ, for the PaTH Study Investigators
(2003) The effects Z-IETD-FMK manufacturer of parathyroid hormone and alendronate alone or in
combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215PubMedCrossRef 12. Keaveny TM, Hoffmann PF, Singh M, Palermo L, Bilezikian JP, Greenspan SL, Black DM (2008) Femoral bone strength and its relation to cortical and trabecular changes after old treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res 23:1974–1982PubMedCrossRef 13. DNA Damage inhibitor Macdonald HM, Nishiyama KK, Hanley DA, Boyd SK (2011) Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis. Osteoporos Int 22:357–362PubMedCrossRef 14. Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB (2007) Effects of a one-month treatment with PTH(1–34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 22:495–502PubMedCrossRef 15. Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL (2003) Effects of teriparatide [recombinant human parathyroid hormone (1–34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539–543PubMedCrossRef 16. Seeman E (2002) Pathogenesis of bone fragility in women and men. Lancet 359:1841–1850PubMedCrossRef 17. Seeman E (2003) Periosteal bone formation-a neglected determinant of bone strength. N Engl J Med 349:320–323PubMedCrossRef 18.